Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-210272
Filing Date
2026-05-07
Accepted
2026-05-07 07:00:41
Documents
62
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q nams-20260331.htm   iXBRL 10-Q 1594733
2 EX-31.1 nams-ex31_1.htm EX-31.1 17537
3 EX-31.2 nams-ex31_2.htm EX-31.2 17494
4 EX-32.1 nams-ex32_1.htm EX-32.1 9853
5 EX-32.2 nams-ex32_2.htm EX-32.2 9827
  Complete submission text file 0001193125-26-210272.txt   7473671

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nams-20260331.xsd EX-101.SCH 1238728
66 EXTRACTED XBRL INSTANCE DOCUMENT nams-20260331_htm.xml XML 1293671
Mailing Address GOOIMEER 2-35 NARRDEN P7 1411 DC
Business Address GOOIMEER 2-35 NARRDEN P7 1411 DC 35 206 2971
NewAmsterdam Pharma Co N.V. (Filer) CIK: 0001936258 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41562 | Film No.: 26950759
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)